Terbinafine 125mg: Clinical Use and Recommendations
A 125 mg oral terbinafine tablet is appropriate specifically for pediatric patients weighing 20-40 kg, though it is not licensed for children in the UK. The standard adult dose remains 250 mg daily, and this lower dose should not be used in adults as it provides subtherapeutic drug levels 1.
Patient Selection for 125mg Dosing
Pediatric Weight-Based Dosing
The 125 mg dose is indicated for:
- Children weighing 20-40 kg: 125 mg daily 1, 2
- Children weighing <20 kg: 62.5 mg daily (half of 125 mg tablet) 1, 2
- Children weighing >40 kg: 250 mg daily (adult dose) 1, 2
Important caveat: Terbinafine is not licensed for pediatric onychomycosis in the UK, though it has extensive off-label use with demonstrated safety 1. For tinea capitis, it is increasingly used off-label in children 3.
Species-Specific Considerations
The 125 mg dose effectiveness varies by organism:
- Trichophyton species (T. tonsurans, T. violaceum): Standard 125 mg dose effective 3
- Microsporum canis: Requires doubled dose (250 mg) even in children 20-40 kg due to higher MIC and poor drug incorporation into hair shafts in prepubertal children 3, 4
Duration of Treatment
For Onychomycosis (Off-Label in Children)
For Tinea Capitis (Off-Label)
- Trichophyton infections: 4 weeks at standard dose 3, 5
- Microsporum canis: 8-12 weeks at doubled dose (250 mg) 4
Shorter durations (1-2 weeks) show significantly lower cure rates and are not recommended 5.
Mandatory Monitoring
Baseline Testing (Before Starting Treatment)
- Liver function tests (ALT, AST)
- Complete blood count
Additional Baseline Monitoring Indicated For:
- History of heavy alcohol consumption 1
- History of hepatitis 1
- Pre-existing hematological abnormalities 1
- All pediatric patients (since unlicensed in children) 1
During Treatment
- Periodic liver function monitoring recommended, especially if treatment exceeds 6 weeks 6
- Monitor complete blood counts if treatment continues >6 weeks in immunocompromised patients 6
- Discontinue immediately if LFTs become elevated 6
Contraindications
Absolute contraindications 1, 6:
- Active or chronic liver disease
- History of allergic reaction to terbinafine (risk of anaphylaxis)
Relative contraindications 1:
- Severe renal impairment (CrCl ≤50 mL/min) - inadequately studied
- Hepatic impairment
Critical Safety Warnings
Potentially Permanent Adverse Effects
Patients must be warned about 6:
- Taste disturbance: Can be permanent; severe enough to cause weight loss and depression
- Smell disturbance: Can be permanent (>1 year or indefinite)
- Both warrant immediate discontinuation if they occur
Serious Hepatotoxicity
- Cases of liver failure requiring transplant or causing death have occurred 6
- Instruct patients to report immediately: persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale stools 6
- Discontinue drug and evaluate liver function emergently if these symptoms develop 6
Other Serious Reactions
- Stevens-Johnson syndrome and toxic epidermal necrolysis (discontinue if progressive rash) 1, 6
- Severe neutropenia (discontinue if neutrophil count <1,000/mm³) 6
- Can precipitate or exacerbate lupus erythematosus 6
- Can aggravate psoriasis 1
Drug Interactions
Minimal interactions overall, but important exceptions 1:
- CYP2D6 substrates: Terbinafine is a potent CYP2D6 inhibitor
- Rifampin: Increases terbinafine clearance 100% 6
- Cimetidine: Decreases terbinafine clearance 33% 6
- Fluconazole: Increases terbinafine exposure by 52-69% 6
Common Pitfalls to Avoid
- Do not use 125 mg in adults - this is a subtherapeutic dose
- Do not use standard pediatric dosing for M. canis - requires doubled dose 4
- Do not skip baseline monitoring in children - unlicensed use requires extra vigilance 1
- Do not continue if taste/smell changes occur - may become permanent 6
- Do not combine with tamoxifen - reduces cancer treatment efficacy 7